WartsNCT06973473
Combination Therapy of Imiquimod 5%Cream and Cryotherapy vs Monotherapy for Common Warts:Randomized Comparative Trial.
An observational study of Warts, run by Assiut University.
Trial summary
To assess the clinical efficacy and safety of topical imiquimod 5% cream combined with cryotherapy versus either of theme alone for the treatment of common warts by clinical and dermoscopic assessments. Read more about this study
- Who is it for?
- Ages 18 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Warts
- How many people
- 60 participants
- Where
- No sites listed yet
- Study dates
- 1 Jul 2025to 1 Aug 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Study population: - study population age older than 18years
Who may be able to join
- Patients with common warts diagnosed clinically and by dermoscopy.
- Patients older than 18years old.
Who cannot join
- Pregnancy and lactation.
- Immunosuppression or being under any kind of treatment causing
- absolute or relative immunosuppression.
- Patients with chronic systemic diseases.
- All cases of bleeding tendency or using anticoagulants.
- Concurrent use of systemic or topical treatments of warts in the last 4 weeks.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
Eman Fathy Ahmed Lecturer of Dermatology, Venereology and Andrology Faculty of contact
About this study
Official title: Aprospective,Randomized,Comparative Clinical Trial of Combination Therapy of Imiquimod 5%Cream and Cryotherapy vs Monotherapy for Common Warts.
To assess the clinical efficacy and safety of topical imiquimod 5% cream combined with cryotherapy versus either of theme alone for the treatment of common warts by clinical and dermoscopic assessments.
Read the detailed description
Topical Imiquimod 5% cream Combined with Cryotherapy Versus either of them alone in Treatment of Common Warts: A prospective Randomized Comparative Trial
- Conditions
- Warts
- Medical subject headings
- Warts
What is being measured
The primary outcome is the main question the study is designed to answer.
Complete clearance rate of common warts.
Assessment of complete warts clearance rate at 12weeks to evaluate the efficacy of combination therapy ( imiquimod5%cream+cryotherapy ) compared to topical imiquimod5%cream alone or cryotherapy alone in patients with common wart.
Measured: 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 May 2025
- Study start1 Jul 2025 (estimated)
- Primary completion1 Jul 2026 (estimated)
- Study completion1 Aug 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for WartsStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Doaa yahia mohamed hassan, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06973473
- Sponsor's protocol ID
- Treatment of common warts
- Status last verified
- May 2025
- First submitted
- 29 Apr 2025
- Last updated
- 15 May 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Aprospective,Randomized,Comparative Clinical Trial of Combination Therapy of Imiquimod 5%Cream and Cryotherapy vs Monotherapy for Common Warts.
- ClinicalTrials.gov ID
- NCT06973473
- Acronym / sponsor ID
- Treatment of common warts
- Conditions
- Warts
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 1 Jul 2025 (estimated)
- Primary completion
- 1 Jul 2026 (estimated)
- Study completion
- 1 Aug 2026 (estimated)
- First posted
- 15 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To assess the clinical efficacy and safety of topical imiquimod 5% cream combined with cryotherapy versus either of theme alone for the treatment of common warts by clinical and dermoscopic assessments.
Detailed description
Topical Imiquimod 5% cream Combined with Cryotherapy Versus either of them alone in Treatment of Common Warts: A prospective Randomized Comparative Trial
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- - study population age older than 18years
Key inclusion criteria (2 listed)
- Patients with common warts diagnosed clinically and by dermoscopy.
- Patients older than 18years old.
Key exclusion criteria (6 listed)
- Pregnancy and lactation.
- Immunosuppression or being under any kind of treatment causing
- absolute or relative immunosuppression.
- Patients with chronic systemic diseases.
- All cases of bleeding tendency or using anticoagulants.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Complete clearance rate of common warts.
Time frame: 12 weeks
Assessment of complete warts clearance rate at 12weeks to evaluate the efficacy of combination therapy ( imiquimod5%cream+cryotherapy ) compared to topical imiquimod5%cream alone or cryotherapy alone in patients with common wart.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 May 2025.
- Individual participant dataSharing planned: No
Related trials for Warts
RecruitingObservational study
Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia
Idiopathic CD4+ Lymphocytopenia, Cryptococcal Meningitis
Not yet recruiting
Efficacy and Safety of Oral Ivermectin for Genital Warts
Genital Warts
Enrolling by invitationPhase 1/2
Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIM
WHIM, Warts
Active, not recruitingPhase 3
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)
Common Warts, Common Warts (Verruca Vulgaris)
RecruitingPhase 3
Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)
Common Warts (Verruca Vulgaris), Common Warts
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Eman Fathy Ahmed Lecturer of Dermatology, Venereology and Andrology Faculty of contact
Questions about this trial
What is this clinical trial studying?
An observational study of Warts, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 15 May 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Eman Fathy Ahmed Lecturer of Dermatology, Venereology and Andrology Faculty of (00201002258614, dr.emanfathy@aun.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Complete clearance rate of common warts. (time frame: 12 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 May 2025.